The VICTORIA-1 trial showed an unprecedented benefit for the gedatolisib triplet, with a hazard ratio of 0.24 in PIK3CA wild-type patients. The dramatic improvement suggests that PAM pathway activation is a dominant resistance mechanism even without a PIK3CA mutation, opening a new treatment avenue.

For high-risk patients with a PIK3CA mutation who progress while on or shortly after adjuvant endocrine therapy, the triplet regimen of enovalisib, a CDK4/6 inhibitor (palbociclib), and fulvestrant is a preferred, aggressive first-line metastatic treatment.

Patients with PIK3CA mutations have shorter progression-free survival but still benefit from adding pertuzumab. This identifies the mutation as a prognostic marker for a poorer outcome, not a predictive marker of resistance to the dual HER2 blockade itself.

The INOVO-123 trial strategically investigates a PI3K inhibitor-based triplet therapy for endocrine-sensitive, PIK3CA-mutated breast cancer. This moves beyond its current approval in the endocrine-resistant setting, aiming to establish its efficacy for patients with de novo metastatic disease or as a first-line treatment, thereby widening its use much earlier in the patient journey.

The VICTORIA-1 trial found that gedatolisib, a pan-PI3K/mTOR inhibitor, significantly improves progression-free survival in patients with PIK3CA *wild-type* tumors after CDK4/6 inhibitor progression. This is a crucial finding for a patient group lacking clear targeted options and broadens the utility of targeting the PI3K pathway beyond just mutated tumors.

While PI3K pathway alterations are linked to a poor prognosis, real-world data provides reassurance for a common clinical dilemma. Patients with co-mutations in both ESR1 and PI3K pathways still achieve significant benefit from elacestrant monotherapy, with progression-free survival (5.2-6.3 months) comparable to the overall population in the pivotal EMERALD trial.

Not all mutations are equal. PIK3CA alterations are often present from the start (truncal mutations), indicating a more aggressive cancer. In contrast, ESR1 mutations are typically acquired later as a direct mechanism of resistance to endocrine therapy, making repeat testing after disease progression crucial.

Post-approval studies of the oral SERD elacestrant confirm its clinical benefit in ESR1-mutant breast cancer. However, this real-world evidence also reveals a new insight: patients who have both an ESR1 and a PIK3CA mutation tend to have a shorter time on treatment, suggesting that the PIK3CA mutation may drive resistance to this therapy.

The Victoria 1 study showed that adding a CDK4/6 inhibitor (triplet therapy) improved outcomes only in patients with PIK3CA wild-type tumors. In PIK3CA-mutant tumors, the doublet therapy was equally effective. This surprising finding highlights that distinct resistance mechanisms are at play and that mutation status is critical for selecting optimal combination regimens.